Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural…
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents…
In 2026, AI investment is shifting from experimentation to deployment, with measurable ROI now a core requirement. Datatonic highlights the…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT…
Lommel / Hamburg, 01/15/2026 – Aqua free, a leading provider of innovative drinking-water hygiene solutions, has successfully moved into its new,…
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…
Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named Interim CEO Alex Blyth, Founder and CEO to step…